By Lauren R. Hartman, Senior Editor
Being an innovator has its ups and downs. At the Orlando, FL, operation of fast-growing Nephron Pharmaceuticals Corp., the ups are in full swing. The company's everexpanding respiratory therapy solutions production plant in Orlando is now packaging single, unit-of-use, sterile, low-density polyethylene vials containing 0.5-percent sterile albuterol sulfate inhalation solution. The Nephron product is the first drug in a unit-of-use container to be approved by the U.S. Food and Drug Administration.
Extrusion/blow-molded in a modified process using transparent LDPE that allows viewing of the liquid content in a shatter-resistant yet easy-to-twist-open container, the 1/2-mL unit-of-use vial of nonpreserved albuterol sulfate inhalation solution should let consumers breathe a bit easier. The premeasured vial is individually packaged in a foil-laminated pouch. Until now, the product was available only in larger quantities in multi-dose bottles containing 10, 20 or 30 mL that had to be measured using a calibrated dropper. Nephron's innovative new vial package containing the 0.5-percent, 0.5-mL premeasured medication allows patients to open a single, sterile, disposable container that eliminates the measuring dropper and provides a specific quantity of the drug every time.